All News
Specific ACPAs and Autoantibodies Lead to RA-Associated ILD
A BRASS registry study shows that specific isotypes of anti-citrullinated protein antibodies (ACPAs) can be associated with incident rheumatoid arthritis-associated ILD (RA-ILD).
Read Article
EHR study of UK Clinical Practice Research Datalink studied 318 hospitalized gout pts showing there is a 30d increased risk of VTE after gout flare aIRR 2.31 (1.39-3.82), that disappeared 31-90d after. https://t.co/h2v8KbiSwX https://t.co/gsfnR50gTD
Links:
Dr. John Cush RheumNow ( View Tweet)
Vision Loss with ANCA-Associated Vasculitis
Shelley K. Dhillon, MD, presents her poster at RWCS 2023.
https://t.co/e25SFDXk7O https://t.co/J1AsdE3b0Y
Links:
Dr. John Cush RheumNow ( View Tweet)
Danish Pop. study of frequency of TMJ and oro-facial Dz in 613 pts w/ #JIA followed 4 yrs. Cumulative incidence of TMJ dz was 30%; 21% had arthritis-induced dentofacial deformity & dentofacial dysfunction (52%). TMJ predicted by younger onset, F, ANA+ https://t.co/M39q3snO3n https://t.co/ajPz27lmvt
Links:
Dr. John Cush RheumNow ( View Tweet)
Tigulixostat is a non-purine xanthine oxidase inhibitor studied in 143 gout pts vs PBO with goal of SUA < 5. TIG was effective at 50mg (47%), 100 mg (45% ), 200 mg (62%) vs PBO 2.6% at week 12; w/ more gout flares in PBO Rx pts (13% vs 9%) https://t.co/d9lAjCBUmZ https://t.co/BERW51HW2B
Links:
Dr. John Cush RheumNow ( View Tweet)
PR3 autoreactive CD4+T cells found in affected kidneys of 72 pts with PR3+ ANCA assoc vasculitis. These cytotoxic GPR56+CD4+T cells were significantly greater in those with inactive (vs active GPA), suggesting they may be affected by immunosuppression
https://t.co/dHFhgnB8yE https://t.co/ZxV6INeCrU
Links:
Dr. John Cush RheumNow ( View Tweet)
Gingival Inflammation Parallels Saliva “Cytokine Score”
Researchers at NYU College of Dentistry have developed a single score to describe the level of cytokines in the saliva, and this score is linked with the severity of clinical gum inflammation.
https://t.co/yIk4ddETeh https://t.co/6KNPe77LIV
Links:
Dr. John Cush RheumNow ( View Tweet)
New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
https://t.co/vw4CMf6F0R https://t.co/moJcOr1LYf
Links:
Dr. John Cush RheumNow ( View Tweet)
Differential Dx of Granulomatous Myopathy: Sarcoidosis, inclusion-body myositis, myasthenia gravis, Crohns, GPA, TB, brucellosis, syphilis, PBC, RA, systemic sclerosis , lymphoma, checkpoint inhibitors, GVHD, natural killer/T-cell lymphoma https://t.co/5IUaC1ln7G https://t.co/guYtvyaaHU
Links:
Dr. John Cush RheumNow ( View Tweet)
S.Korean population based study shows the frequency of pregnancy induced de Quervain's tenosynovitis (DQT) between 2013-17 was 2.1% of all preg women. Risk factors: ≥ 30 yrs, multiple gestation, C-Section, HTN in preg, RA (DM not a risk) https://t.co/JaOQhaX5rL https://t.co/cl6RZLfXds
Links:
Dr. John Cush RheumNow ( View Tweet)
IgG4 levels are often elevated and helpful, but not always. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/GLPWyXVLgq https://t.co/8rdXpGYWRZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Steroids assisting options - CTX, LEF or RTX @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/gVw2tGKYNG https://t.co/ItIKB8MFTI
Links:
Dr. John Cush RheumNow ( View Tweet)
Future therapies for IgG4 re dz. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/oDgCUD0Crr https://t.co/0QSrrxmeqM
Links:
Dr. John Cush RheumNow ( View Tweet)
Case reports of anifrolumab use in 2 pts w/ chronic, scarring discoid lupus unresponsive to steriods, HCQ, immunosuppressants & CTX. Case 1 SLEDAI from 13 to 2 in 24 weeks & CLASI-A from 26 to 3 in 20wks. Cs 2 CLASI-A decr 24 to 5 after 1 infusion https://t.co/Qe2rF4Avxe
Links:
Dr. John Cush RheumNow ( View Tweet)
Implantable Vagal nerve stimulation studied in 17 active #RA pts DAS ~6. Dr Eric Ruderman #RWCS23 https://t.co/GgjdcfuVud https://t.co/EpuGgApOq5
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of HBV reactivation in HBsAg−/HBcAb+ RA ( 26 studies 2252 pts) Rx w/
b/tsDMARDs. Pooled HBV reactivation = 2%. Reactivation higher w/ RTX (esp if HBsAb−)
RTX 9% (p .03)
ABA 6%
JAKi 1%
IL‐6i 0%
TNFi 0%
Safe to use TNFi, JAKi, IL6 mAbs
https://t.co/U76or69bnB https://t.co/5QbR3WqzUG
Links:
Dr. John Cush RheumNow ( View Tweet)
Your #RA patient clearly has active disease that requires new Rx. Is your choice driven by:
Dr. John Cush RheumNow ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Will we see you there?
https://t.co/Pv5hywp0ZQ https://t.co/lux83rqNfz
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Methotrexate Increase Skin Cancer Risk?
A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses.
https://t.co/8AkdkrZs44 https://t.co/ZXrqlbZiZV
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE.
https://t.co/YS8n02BEsk https://t.co/4sBd88AhtK
Links:
Dr. John Cush RheumNow ( View Tweet)